Evidence map›Paper›PMID 36275724›Full record

ArticleFrontiers in immunology2022

Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching.

Shao-Wu Jing, Chang Zhai, Wei Zhang, Ming He, Qing-Yi Liu, Ji-Fang Yao, Rui Wang, Zi-Qiang Tian, Jun Wang, Jun-Feng Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 3 pooled it
8.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Shao-Wu JingDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Chang ZhaiDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Wei ZhangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ming HeDepartment of Cardiothoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Qing-Yi LiuDepartment of Cardiothoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Ji-Fang YaoDepartment of Cardiothoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Rui WangDepartment of Cardiothoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Zi-Qiang TianDepartment of Cardiothoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jun WangDepartment of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Jun-Feng LiuDepartment of Cardiothoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Fourth Hospital of Hebei Medical University · CNHebei Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Clinical studies on immune checkpoint inhibitors (ICIs) combined with neoadjuvant chemotherapy (nCT) have been carried out for the resectable esophageal squamous cell carcinoma (ESCC). So far, few studies have compared the survival outcomes of nCT plus ICIs and nCT alone. This study aimed to compare the efficacy and safety of neoadjuvant ICIs combined with nCT versus nCT followed by esophagectomy for patients with resectable locally advanced ESCC. Methods: A retrospective analysis of ESCC patients underwent nCT or nCT combined with ICIs followed by esophagectomy (from March 2013 to April 2021) was performed. A 1:1 propensity score matching (PSM) with a caliper 0.01 was conducted to balance potential bias. Results: A total of 47 comparable pairs of ESCC patients receiving nCT and nCT combined with ICIs were selected for the final analysis. The tumor regression grade (TRG) 0 and pathologic complete response (pCR) rates in the nCT+ICIs group were significantly higher than those of the nCT group (21.7% vs. 4.5%, Conclusions: Compared with nCT alone, neoadjuvant immunotherapy plus nCT for patients with locally advanced ESCC has an advantage in pathological response, and could improve DFS with a good safety and feasibility, while long term survival validation is still needed further.

Indexed as

Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaAntineoplastic Combined Chemotherapy ProtocolsHumansImmune Checkpoint InhibitorsImmunotherapyNeoadjuvant TherapyPropensity ScoreRetrospective StudiesImmune Checkpoint Inhibitorsesophageal squamous cell carcinomaesophagectomy (or surgery)immune checkpoint inhibitorsneoadjuvant chemotherapypropensity score matching

Identifiers

PMID36275724
PMCPMC9585292
OpenAlexW4303183116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.